Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630409 | 0.82 | SLC29A1 (0.49) | ADORA3TSHRNFKB1BLMPMP22 | |
| SCHEMBL1797537 | 0.81 | PAX8 (0.61) | PAX8ADORA3TSHRADORA2AADORA1 | |
| SCHEMBL18630613 | 0.79 | ADORA3 (0.52) | ADORA3TSHR | |
| SCHEMBL18630524 | 0.77 | ADORA3 (0.56) | ADORA3TSHRNFKB1 | |
| SCHEMBL23080199 | 0.77 | SLC29A1 (0.49) | PAX8ADORA3TSHRADORA2AADORA1 | |
| SCHEMBL18630476 | 0.77 | DNPH1 (0.49) | — | |
| SCHEMBL12567224 | 0.76 | ADORA3 (0.44) | PAX8ADORA3TSHRADORA2AADORA1 | |
| SCHEMBL18630399 | 0.76 | ADORA2B (0.46) | ADORA3TSHRADORA2AADORA1NFKB1 | |
| SCHEMBL18631613 | 0.75 | ATG7 (0.44) | ADORA3TSHRADORA2AADORA1NFKB1 | |
| SCHEMBL18630397 | 0.75 | NAE1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PAX8 4188/4885ADORA3 3584/4885TSHR 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.